GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 1 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,088,000 | +124.0% | 30,664 | +5.1% | 0.02% | +150.0% |
| Q2 2022 | $932,000 | -12.5% | 29,170 | -5.2% | 0.01% | 0.0% |
| Q1 2022 | $1,065,000 | +10.5% | 30,755 | -6.6% | 0.01% | +20.0% |
| Q4 2021 | $964,000 | +15.4% | 32,919 | +0.5% | 0.01% | +25.0% |
| Q3 2021 | $835,000 | -28.9% | 32,758 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $1,174,000 | +2074.1% | 33,536 | +2419.6% | 0.00% | – |
| Q1 2021 | $54,000 | -16.9% | 1,331 | -10.7% | 0.00% | – |
| Q4 2020 | $65,000 | -22.6% | 1,490 | -2.7% | 0.00% | – |
| Q3 2020 | $84,000 | -16.8% | 1,531 | -4.4% | 0.00% | – |
| Q2 2020 | $101,000 | -94.2% | 1,601 | -95.3% | 0.00% | -100.0% |
| Q1 2020 | $1,752,000 | -39.3% | 34,293 | -5.5% | 0.01% | -9.1% |
| Q4 2019 | $2,884,000 | +62.5% | 36,275 | -0.8% | 0.01% | +57.1% |
| Q3 2019 | $1,775,000 | -2.5% | 36,580 | +5.7% | 0.01% | 0.0% |
| Q2 2019 | $1,821,000 | +0.8% | 34,619 | +1.4% | 0.01% | 0.0% |
| Q1 2019 | $1,807,000 | +33.9% | 34,140 | +3.8% | 0.01% | +16.7% |
| Q4 2018 | $1,350,000 | +7.1% | 32,897 | -0.8% | 0.01% | +50.0% |
| Q3 2018 | $1,260,000 | -14.3% | 33,149 | +1.8% | 0.00% | -20.0% |
| Q2 2018 | $1,471,000 | +22.3% | 32,551 | +30.7% | 0.01% | +25.0% |
| Q1 2018 | $1,203,000 | +22.9% | 24,897 | +0.1% | 0.00% | +33.3% |
| Q4 2017 | $979,000 | +27.3% | 24,869 | +0.5% | 0.00% | 0.0% |
| Q3 2017 | $769,000 | +22.8% | 24,752 | +8.1% | 0.00% | +50.0% |
| Q2 2017 | $626,000 | +69.2% | 22,902 | +128.3% | 0.00% | +100.0% |
| Q1 2017 | $370,000 | +216.2% | 10,031 | +24.1% | 0.00% | – |
| Q4 2016 | $117,000 | -99.9% | 8,086 | -0.3% | 0.00% | -100.0% |
| Q3 2016 | $186,889,000 | +39.1% | 8,108 | +0.1% | 0.00% | 0.0% |
| Q2 2016 | $134,313,000 | +113.2% | 8,096 | +104.2% | 0.00% | – |
| Q1 2016 | $63,000,000 | – | 3,965 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |